Role of interleukin 10 in murine postoperative ileus

Background and aims: Intestinal manipulation triggers an inflammatory cascade within the muscularis causing postoperative ileus (POI). The aim of this study was to investigate the recovery and therapeutic potential of interleukin 10 (IL10) for POI. Methods: POI was induced by bowel surgical manipulation (SM) in wild-type, IL10 y and recombinant murine IL10 (rmlLIO)-treated mice. Immunohistochemistry localised IL10 in the muscularis externa, histochemistry quantified neutrophil recruitment, and quantitative PCR quantified alterations in mRNA. Luminex multiplex analysis, Griess reaction and ELISA measured proteins, nitric oxide (NO) and prostanoid release from the muscularis externa, respectively, in 24 h organ culture. Gastrointestinal transit and jejunal circular muscle organ bath techniques assessed gastrointestinal function. Results: In IL10 knockouts compared with the wild type, the expression of numerous proinflammatory mRNAs (IL6, IL1(3, chemokine C-C motif ligand 2 (CCL2) and haem oxygenase-1) and proteins (IL6, IL1a, IL12, IL17, interferon y, tumour necrosis factor a, CCL2, interferon-inducible protein-10 and granulocyte-macrophage colony-stimulating factor (GM-CSF)) were accentuated, and release of muscle inhibitors NO and prostanoids was increased; motility never recovered from manipulation and mortality rate was 87.5%. In wild types, complete functional recovery occurred in 7 days with no mortality. SM delay in transit and suppression in jejunal circular muscle contractions were significantly improved by rmlLIO treatment. Upregulation in IL1(3, IL6 and CCL2 mRNAs and inflammatory mediators (IL1a, IL6, CCL2, macrophage inflammatory protein-1a, GM-CSF, NO and prostaglandin) after SM were significantly less with rmlLIO treatment, which resulted in a decrease in neutrophil recruitment compared with SM controls. Conclusion: IL10 plays an obligatory role in postoperative intestinal recovery, and exogenous IL10 prevents its development. Preemptive exogenous recombinant human IL10 could be a treatment for the prevention of clinical POI.